Advertisement
Advertisement
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 75.82 |
| Open | 75.88 |
| Bid | 75.36 x 900 |
| Ask | 75.37 x 800 |
| Day's Range | 75.22 - 76.14 |
| 52 Week Range | 61.45 - 89.74 |
| Volume | |
| Avg. Volume | 5,505,420 |
| Market Cap | 93.787B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 17.30 |
| EPS (TTM) | 4.35 |
| Earnings Date | Oct 25, 2023 - Oct 30, 2023 |
| Forward Dividend & Yield | 3.00 (3.96%) |
| Ex-Dividend Date | Sep 14, 2023 |
| 1y Target Est | 85.23 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
41% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Gilead Sciences, Inc.Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 17,000 employees.RatingFair ValueEconomic Moat3 days agoArgus Research
Motley Fool3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
The Wall Street JournalBlockbuster Cancer Treatment Stymied by Supply Chain—for Now
A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner Legend, if they can increase manufacturing.
ZacksGilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
